<DOC>
	<DOC>NCT02646137</DOC>
	<brief_summary>Hepatocellular carcinoma is the third most common cause of cancer-related mortality. In recent years, transarterial chemoembolization, radio frequency ablation and microwave ablation have been accepted as treatment modalities for patients with surgically unresectable hepatocellular carcinoma.</brief_summary>
	<brief_title>Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma</brief_title>
	<detailed_description>To compare between combination treatment with radiofrequency or microwave ablation followed by transarterial chemoembolization and performed in a single session.</detailed_description>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Child classification A or B. serum albumin ≥ 3 gm/L. serum bilirubin &lt; 2.5 mg/dL. platelet count ≥70,000 mm3. INR ≤ 1.6. serum creatinine &lt; 2 mg/dl. tumor size more than 4 cm and confined to one lobe of the liver. Patients with portal vein thrombosis. A technically inaccessible hepatic artery. Metastatic HCC. More than three lesions. lesions in close proximity to the portal vein (PV),inferior vena cava (IVC) or gall bladder were excluded from the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>